Karnik Sonali J, Margetts Tyler J, Wang Hannah S, Movila Alexandru, Oblak Adrian L, Fehrenbacher Jill C, Kacena Melissa A, Plotkin Lilian I
Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA.
Curr Osteoporos Rep. 2024 Feb;22(1):165-176. doi: 10.1007/s11914-023-00847-x. Epub 2024 Jan 29.
This review examines the linked pathophysiology of Alzheimer's disease/related dementia (AD/ADRD) and bone disorders like osteoporosis. The emphasis is on "inflammaging"-a low-level inflammation common to both, and its implications in an aging population.
Aging intensifies both ADRD and bone deterioration. Notably, ADRD patients have a heightened fracture risk, impacting morbidity and mortality, though it is uncertain if fractures worsen ADRD. Therapeutically, agents targeting inflammation pathways, especially Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and TNF-α, appear beneficial for both conditions. Additionally, treatments like Sirtuin 1 (SIRT-1), known for anti-inflammatory and neuroprotective properties, are gaining attention. The interconnectedness of AD/ADRD and bone health necessitates a unified treatment approach. By addressing shared mechanisms, we can potentially transform therapeutic strategies, enriching our understanding and refining care in our aging society. This review article is part of a series of multiple manuscripts designed to determine the utility of using artificial intelligence for writing scientific reviews.
本综述探讨阿尔茨海默病/相关痴呆（AD/ADRD）与骨质疏松等骨疾病之间相关的病理生理学。重点在于“炎症衰老”——二者共有的一种低度炎症，及其在老年人群中的影响。
衰老会加剧ADRD和骨质恶化。值得注意的是，ADRD患者骨折风险增加，这会影响发病率和死亡率，不过骨折是否会使ADRD恶化尚不确定。在治疗方面，针对炎症途径的药物，尤其是活化B细胞核因子κB（NF-κB）和肿瘤坏死因子-α（TNF-α），似乎对这两种病症都有益。此外，具有抗炎和神经保护特性的沉默调节蛋白1（SIRT-1）等治疗方法也受到关注。AD/ADRD与骨骼健康的相互关联需要统一的治疗方法。通过解决共同机制，我们有可能改变治疗策略，增进我们的理解，并在老龄化社会中优化护理。这篇综述文章是一系列多篇手稿的一部分，这些手稿旨在确定使用人工智能撰写科学综述的效用。
